Exelixis Inc EXEL

Exelixis Inc is an American biotechnology company based in Alameda, California. Operating internationally, the firm is predominantly an oncology-focused, genomics-based research and drug discovery company involved in the discovery, development, and commercialisation of new therapies aimed at patients suffering from cancers that are traditionally difficult to treat. The firm was founded in 1994.

The company is the producer of Cometriq, a treatment approved by the US Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer, and Cabometyx, a treatment for patients with advanced renal cell carcinoma. Other commercial products include Cotellic, a kinase inhibitor used in the treatment of patients with unresectable or metastatic melanoma.

The firm has several other products in the pipeline at various stages, with a strong focus on small molecule drug discovery and biotherapeutic treatments primarily aimed at cancer patients. Exelixis Inc has acquired various related companies, including Genomica, Agritope, and X-Ceptor. The firm also collaborates with a number of partners in the industry, such as Invenra, who Exelixis Inc is working with on the development of cancer antibodies, antibody-drug conjugates, and other biologic candidates. The firm trades on the NASDAQ, where it is listed under the stock ticker EXEL.

Track price movements by adding EXEL stock to your eToro watchlist.